

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/84, C07C 49/15, 225/20, A61K 31/12, 31/44, C07D 211/00		A1	(11) International Publication Number: WO 96/14300
			(43) International Publication Date: 17 May 1996 (17.05.96)
(21) International Application Number: PCT/US95/14597		(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
(22) International Filing Date: 25 October 1995 (25.10.95)			
(30) Priority Data: 08/334,475 4 November 1994 (04.11.94) US			
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors: BUTERA, John, Anthony; 6 Lawrence Spring Drive, Clarksburg, NJ 08510 (US). ANTANE, Schuyler, Adam; 14214 Marie Court, Lawrenceville, NJ 08648 (US). HIRTH, Bradford, Hammond; 4 Dogwood Road, Littleton, MA 01460 (US).			
(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Five Giralda Farms, Madison, NJ 07940-0874 (US) et al.			

(54) Title: **N-ARYL AND N-HETEROARYL-1,2-DIAMINOCYCLOBUTENE-3,4-DIONES WITH SMOOTH MUSCLE RELAXING ACTIVITIES**

(57) Abstract

The compounds of formula (I), wherein R₁ is hydrogen, C₁₋₁₀ straight or branched chain alkyl, C₃₋₁₀ cyclic or bicyclic alkyl, alkanoyl of 2 to 7 carbon atoms, alkylsulfonyl of 1 to 7 carbon atoms, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms; R₂ is hydrogen, C₁₋₁₀ straight or branched chain alkyl or C₃₋₁₀ cyclic or bicyclic alkyl; A is a group of formula (II), wherein R₇ and R₈, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, carboalkoxy of 2 to 7 carbon atoms, hydroxyl or hydrogen; or A is Het where Het is selected from (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), wherein R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, C₁₋₆ alkylsulfonamido, C₂₋₆ alkylcarboxamido, nitro, cyano, carboxyl, chloro, bromo, fluoro, iodo; n is an integer from 0 to 6; R₃ and R₄ are, independent from each other, hydrogen, C₁₋₁₀ straight or branched chain alkyl, or C₃₋₁₀ cyclic or bicyclic alkyl; C₁₋₁₀ perfluoroalkyl, C₁₋₁₀ hydroxyalkyl, C₂₋₁₀ alkoxyalkyl, fluoro; or, when taken together, form a spirocyclic ring containing a total of 3-7 carbon atoms; R₅ and R₆, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, C₂₋₇ carboalkoxy, hydroxyl, or hydrogen; or a pharmaceutically acceptable salt thereof.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

N-Aryl and N-Heteroaryl-1,2-Diaminocyclobutene-3,4-diones with smooth muscle relaxing activities

Background of Invention

5

The present invention relates to novel 1, 2-diamino derivatives of cyclobutene 3-4-diones having pharmacological activity, to a process for their preparation, to pharmaceutical compositions containing them, and to their use in the treatment of disorders associated with smooth muscle contraction; via potassium channel modulation. Such disorders include, but are not limited to: urinary incontinence, hypertension, asthma, premature labor, irritable bowel syndrome, congestive heart failure, angina, and cerebral vascular disease.


Stemp et al. disclose a class of amino substituted cyclobutenedione derivatives of chromans described as having blood pressure lowering activity and bronchodilatory activity in EP-426379-A2. Several series of 1-amino-2-phenylalkylamino-cyclobutene-3,4-diones are reported as H-2 receptor antagonists by Algieri et al. in US Patent 4,390,701 and its numerous divisionals and CIPs. Several related 1-amino-2-phenoxyalkylamino derivatives are disclosed by Nohara et al. in US Patent 4,673,747.

The synthesis of representative 1,2-diamino-cyclobutene-3,4-diones are described in the following publications: Tietze et al., *Chem Ber.* 1991, 124, 1215; Tietze et al., *Bioconjugate Chem.* 1991, 2, 148; Ehrhardt et al., *Chem. Ber.* 1977, 110, 2506, and Neuse et al., *Liebigs Ann. Chem.* 1973, 619.

Description of The Invention

Accordingly, the present invention discloses compounds represented by the formula (I):

- 2 -



(I)

wherein:


5 R_1 is hydrogen, C₁-10 straight or branched chain alkyl, C₃-10 cyclic or bicyclic alkyl, alkanoyl of 2 to 7 carbon atoms, alkylsulfonyl of 1 to 7 carbon atoms, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms;

10

R_2 is hydrogen, C₁-10 straight or branched chain alkyl or C₃-10 cyclic or bicyclic alkyl;

A is a group of the following formula:

15



wherein:

20

R_7 and R_8 , independent from each other, are selected from the following: cyano, nitro, amino, C₁-6 alkyl,


- 3 -

5

C₁-6 perfluoroalkyl, C₁-6 alkoxy, C₁-6 perfluoroalkoxy, amino, C₁-12 mono- or dialkylamino, sulfonamide, C₁-6 alkylsulfonamido, C₆-12 arylsulfonamido, C₂-6 alkylcarboxamido, C₇-12 arylcarboxamido, C₁-6 alkylsulfonyl, C₁-6 perfluoroalkylsulfonyl, C₆-12 arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, carboalkoxy of 2 to 7 carbon atoms, hydroxyl or hydrogen;

10

or, A is Het where Het is selected from the following:



wherein:

- 4 -

R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, C₁₋₆ alkylsulfonamido, C₂₋₆ alkylcarboxamido, nitro, cyano, carboxyl, chloro, bromo, fluoro, iodo;

5

n is an integer from 0 to 6;

10

R₃ and R₄ are, independent from each other, hydrogen, C₁₋₁₀ straight or branched chain alkyl, or C₃₋₁₀ cyclic or bicyclic alkyl; C₁₋₁₀ perfluoro alkyl, C₁₋₁₀ hydroxyalkyl, C₂₋₁₀ alkoxyalkyl, fluoro; or, when taken together, form a spirocyclic ring containing a total of 3-7 carbon atoms;

15

R₅ and R₆, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, C₂₋₇ carboalkoxy, hydroxyl, or hydrogen;

20

or a pharmaceutically acceptable salt thereof.

25

A preferred aspect of this invention includes compounds of formula (I)


wherein:

R₁ and R₂ are as stated above;

30

A is a group of the following formula:

- 5 -




wherein:

5

R7 and R8, independent from each other, are selected from the following: cyano, nitro, amino, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, hydrogen;

or A is Het where Het is selected from the following:



10.

wherein:

R9 is as stated above;

15

n = 0;

- 6 -

R₃ and R₄ are, independent from each other, hydrogen, C₁₋₁₀ straight or branched chain alkyl, C₁₋₁₀ perfluoro alkyl, C₁₋₁₀ hydroxyalkyl or fluoro;

5 R₅ and R₆, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, chloro, bromo, fluoro, iodo, carboxyl, C₂₋₇ carboalkoxy, hydroxyl, hydrogen;

10 or a pharmaceutically acceptable salt thereof.

It is understood that the definition of the compounds of formula (I), when R₁, R₂, R₃, R₄, R₅, or R₆ contain asymmetric carbons, or when R₃ is different from R₄,
15 encompass all possible stereoisomers and mixtures thereof. In particular, it encompasses racemic modifications and optical isomers. The optical isomers may be obtained in pure form by standard separation techniques. The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
20 Where R₃, R₄, R₅ or R₆ are carboxyl groups, salts of the compounds of this invention may be formed with bases such as alkali metals (Na, K, Li) or the alkaline earth metals (Ca or Mg).

25 The acyl groups representing R₁ are derived from such acids as acetic, propionic, butyric, valeric, caproic, methanesulfonic, ethanesulfonic, benzoic, toluic, cinnamic, phenylsulfonic, phenylacetic, naphthylacetic, benzylsulfonic and the like.

30 Examples of alkyl as a group or part of a group, e.g. alkoxy, aryl are alkyl groups of 1-4 carbon atoms such as methyl, ethyl, propyl and butyl.

The term aryl when used for a group or part of a group, e.g. arylalkyl, aroyl, includes carbocyclic aromatic groups of 6 to 10 carbon atoms, e.g. phenyl and naphthyl such as 1-naphthyl.

35


- 7 -

Examples of perfluoroalkyl group are such groups having 1-4 carbon atoms, e.g. perfluoromethyl and perfluoroethyl.

The present invention also provides processes for the preparation of compounds of formula (I). Accordingly, this invention provides a process for preparing a compound of formula I which comprises:


a) reacting a compound of the formula:

10



wherein X is a leaving group and A and R₁ are as defined above, with a compound of formula:

15



wherein n and R₂₋₆ are as defined above to give a compound of formula I; or

20

b) reacting a compound of formula I wherein R₁ is hydrogen with an alkylating or acylating agent containing R₁ where R₁ is as defined above expecting hydrogen in the presence of a base to give a compound of formula I where R₁ is other than hydrogen; or

25

- 8 -

c) converting an acidic compound of formula I wherein at least one of R₅-R₉ is a carboxy group to a salt with a base, e.g. alkali metal, alkaline earth metal or optionally substituted ammonium salt; or

5 d) converting a basic compound of formula I to a pharmaceutically acceptable acid addition salt; or

 e) isolating an optically active isomer of a compound of formula I from a mixture of isomers; or

10

 f) reacting a compound of formula I having a reactive site or substituent group to give a different compound of formula I.

 Conveniently the compounds of formula I may be prepared by reacting a
15 compound of formula II.

 As mentioned previously, the compounds of formula (I) have been found to relax smooth muscle. They are therefore useful in the treatment of disorders associated with smooth muscle contraction, disorders involving excessive smooth
20 muscle contraction of the urinary tract (such as incontinence), or of the gastrointestinal tract (such as irritable bowel syndrome), asthma, and hair loss. Furthermore, the compounds of formula (I) are active as potassium channel activators which render them useful for treatment of peripheral vascular disease, congestive heart failure, stroke, anxiety, cerebral anoxia and other neurodegenerative disorders.

25

 The present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention and a pharmaceutically acceptable carrier. In particular, the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a
30 pharmaceutically acceptable carrier.

 The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration for patients suffering from heart failure.

35

- 9 -

In order to obtain consistency of administration, it is preferred that a composition of the invention is in the form of a unit dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 2 to 50 mg. Still further preferred unit dosage forms contain 5 to 25 mg of a compound of the present invention. The compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg. Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.

The compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that used for known antihypertensive agents, diuretics and β -blocking agents.

The present invention further provides a compound of the invention for use as an active therapeutic substance. Compounds of formula (I) are of particular use in inducing smooth muscle relaxation.

The present invention further provides a method of treating smooth muscle disorders in mammals including man, which comprises administering to the afflicted mammal an effective amount of a compound or a pharmaceutical composition of the invention.

The following examples are presented to illustrate rather than limit the methods for production of representative compounds of the invention.

EXAMPLE 1

4-[3,4-Dioxo-2-((R)-1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile

Step 1) Preparation of 4-(3,4-Dioxo-2-ethoxy-cyclobut-1-enylamino)-benzonitrile

- 10 -

4-Aminobenzonitrile (3.47 g, 29.4 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1, 2-dione (5.00 g, 29.4 mmol) in absolute ethanol (100 mL). The mixture was heated at reflux overnight. The mixture was cooled, and the resulting yellow precipitate was collected by vacuum filtration. Yield: 2.60 g (37%):
5 mp 218-222°C; ¹H NMR (DMSO-d₆): δ 11.07 (s, 1H), 7.81 (d, 2H), 7.56 (d, 2H), 4.79 (q, 2H), 1.46 (t, 3H).

Step 2) Preparation of 4-[3,4-dioxo-2-((R)-1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile

10

To the above squarate (0.50 g, 2.06 mmol) in ethanol (10 mL) was added (R)-α-methylbenzylamine (0.27 mL, 2.1 mmol). The mixture was heated at reflux for 16 hours and vacuum filtered. The precipitate was recrystallized from methanol to afford 0.17 g (26%) of product as a pale yellow solid: mp 273-274°C; [α]_D²⁵ -53.20
15 (DMSO); ¹H NMR (DMSO-d₆): δ 9.91 (s, 1H), 8.21 (d, 1H), 7.72 (d, 1H), 7.79-7.31 (m, 9H), 5.29 (m, 1H), 1.59 (d, 3H). IR (KBr): 3200, 2230, 1790, 1670, 1600 cm⁻¹; MS (m/z) 317 (M⁺).

Elemental analysis for C₁₉H₁₅N₃O₂

20

Calc'd: C, 71.91; H, 4.76; N, 13.24.

Found: C, 71.26; H, 4.86; N, 13.49.

EXAMPLE 2

25

3-(5-Bromo-pyridin-3-ylamino)-4-((R)-1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione

Step 1) Preparation of 3-(5-bromo-pyridin-3-ylamino)-4-ethoxy-cyclobut-3-ene-1,2-dione)

30

3-Amino-5-bromopyridine (1.92 g, 11.3 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (2.24 g, 11.1 mmol) in absolute ethanol (30 mL). The mixture was heated at reflux for 18 hours, cooled and filtered. The filtrate was concentrated and the resulting residue chromatographed (CH₃OH/CH₂Cl₂) to

- 11 -

afford 2.06 g (62%) of product as an off-white solid: ^1H NMR (DMSO- d_6): δ 11.00 (s, 1H), 8.56 (s, 1H), 8.42 (s, 1H), 8.09 (s, 1H), 4.79 (q, 2H), 1.42 (t, 3H).

5 **Step 2)** Preparation of 3-(5-Bromo-pyridin-3-ylamino)-4-((R)-1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione

10 To the above squarate (0.815 g, 2.74 mmol) in ethanol (25 mL) was added (R)- α -methylbenzylamine (0.36 mL, 2.8 mmol). The mixture was heated at reflux for 23 hours. The precipitate was filtered off and rinsed with ethanol to afford 0.92 g (90%) of product as an off-white solid: mp 268-271°C (dec); $[\alpha]^{25}_D$ +6.57 (DMSO); ^1H NMR (DMSO- d_6): δ 9.85 (s, 1H), 8.44-8.15 (m, 4H), 7.43-7.27 (m, 5H), 5.29 (m, 1H), 1.59 (d, 3H). IR (KBr): 3200, 1790, 1670, 1590 cm^{-1} ; MS (m/z) 372 (MH $^+$).

15 Elemental analysis for $\text{C}_{17}\text{H}_{14}\text{BrN}_3\text{O}_2$

 Calc'd: C, 54.86; H, 3.79; N, 11.29.

 Found: C, 54.88; H, 3.67; N, 11.20.

EXAMPLE 3

20 **3-(2-Methoxy-5-trifluoromethyl-phenylamino)-4-((R)-1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione**

Step 1) Preparation of 3-ethoxy-4-(2-methoxy-5-trifluoromethyl-phenylamino)-cyclobut-3-ene-1,2-dione

25 2-Methoxy-5-trifluoromethylaniline (5.62 g, 29.4 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (5.00 g, 29.4 mmol) in absolute ethanol (100 mL). The mixture was heated at reflux for 66 hour, cooled and filtered. The precipitate was purified by chromatography ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) to afford 1.88 g (20%) of product as a yellow solid: ^1H NMR (DMSO- d_6): δ 10.42 (s, 1H), 7.64-7.20 (m, 3H), 4.69 (q, 2H), 3.90 (s, 3H), 1.34 (t, 3H).

35 **Step 2)** Preparation of 3-(2-methoxy-5-trifluoromethyl-phenylamino)-4-((R)-1-phenyl-ethylamine)-cyclobut-3-ene-1,2-dione

- 12 -

To the above squarate (0.806 g, 2.56 mmol) in ethanol (10 mL) was added (R)- α -methylbenzylamine (0.33 mL, 2.6 mmol). The mixture was heated at reflux for 23 hours. The clear yellow solution was concentrated and the resulting foam purified by chromatography (CH₃OH/CH₂Cl₂) to afford 0.84 g (84%) of product as a white solid: mp 115-124°C; [α]_D²⁵ -33.61 (DMSO); ¹H NMR (DMSO-d₆): δ 9.37 (s, 1H), 8.72 (d, 1H), 8.24 (s, 1H), 7.42-7.19 (m, 7H), 5.33 (m, 1H), 3.97 (s, 1H), 1.59 (d, 3H). IR (KBr): 3250, 1790, 1690, 1610 cm⁻¹; MS (m/z) 391 (MH⁺).

Elemental analysis for C₂₀H₁₇F₃N₂O₃
Calc'd: C, 61.54; H, 4.39; N, 7.18.
Found: C, 61.42; H, 4.26; N, 7.23.

EXAMPLE 4

3-((R)-1-Phenyl-ethylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione

Step 1) Preparation of 3-ethoxy-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione

To a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (5.00 g, 29.4 mmol) in ethanol (100 mL) was added a suspension of 4-aminopyridine (2.77 g, 29.4 mmol) in ethanol (50 mL). The reaction mixture was heated at reflux for 4 hours. Concentration and chromatography (EtOAc) of the resulting residue afforded 0.632 g (10%) of product as a white solid: ¹H NMR (DMSO-d₆): δ 11.18 (br s, 1H), 8.45 (d, 2H), 7.40 (d, 2H), 4.80 (q, 2H), 1.43 (t, 3H).

Step 2) Preparation of 3-((R)-1-phenyl-ethylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione

To the above squarate (0.850 g, 3.90 mmol) in ethanol (25 mL) was added (R)- α -methylbenzylamine (0.51 mL, 4.0 mmol). The mixture was heated at reflux for 23 hours. The precipitate was filtered off and rinsed with ethanol. Chromatography (CH₃OH/CH₂Cl₂) afforded 0.276 g (24%) of product as an off-white solid: mp 252-254°C (dec); [α]_D²⁵ -31.45 (DMSO); ¹H NMR (DMSO-d₆): δ 9.82 (s, 1H), 8.40 (d,

- 13 -

2H), 8.22 (d, 1H), 7.45-7.38 (m, 7H), 5.28 (m, 1H), 1.59 (d, 3H). IR (KBr): 3200, 1800, 1675, 1590 cm^{-1} ; MS (m/z) 293 (MH^+).

Elemental analysis for $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_2$

- 5 Calc'd: C, 69.61; H, 5.15; N, 14.33.
 Found: C, 69.49; H, 5.06; N, 14.18.

EXAMPLE 5

10 4-[3,4-Dioxo-2-((S)-1-phenyl-ethylamino)-cyclobut-1-enylaminol-benzonitrile

- To the squarate of Example 1, step 1 (0.50 g, 2.06 mmol) in ethanol (10 mL) was added (S)- α -methylbenzylamine (0.27 mL, 2.1 mmol). The mixture was heated at reflux for 16 hours and vacuum filtered. The precipitate was recrystallized from
15 methanol to afford 0.17 g (26%) of product as a pale yellow solid: mp 269-270°C; $[\alpha]_{\text{D}}^{25} +46.47$ (DMSO); ^1H NMR (DMSO- d_6): δ 9.91 (s, 1H), 8.21 (d, 1H), 7.72 (d, 1H), 7.79-7.31 (m, 9H), 5.29 (m, 1H), 1.59 (d, 3H). IR (KBr): 3200, 2230, 1790, 1670, 1600 cm^{-1} ; MS (m/z) 317 (M^+).

- 20 Elemental analysis for $\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_2$
 Calc'd: C, 71.91; H, 4.76; N, 13.24.
 Found: C, 71.17; H, 4.83; N, 13.34.

EXAMPLE 6

25

3-(4-Trifluoromethoxy-phenylamino)-4-((R)(-)-1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione

- Step 1) Preparation of 3-ethoxy-4-(4-trifluoromethoxy-phenylamino)-
30 cyclobut-3-ene-1,2-dione

- 4-Trifluoromethoxyaniline (5.00 g, 28.2 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (5.00 g, 29.4 mmol) in absolute ethanol (50 mL). The mixture was heated at reflux overnight, then vacuum filtered hot. The
35 filtrate was reduced in volume and the resulting precipitate was filtered to afford 4.50

- 14 -

g (53%) of white solid: mp 145-146°C; ¹H NMR (DMSO-d₆): δ 10.87 (s, 1H), 7.45 (d, 2H), 7.36 (d, 2H), 4.75 (q, 2H), 1.41 (t, 3H).

5 **Step 2) Preparation of 3-(4-trifluoromethoxy-phenylamino)-4-((R)-1-phenyl-ethylamine)-cyclobut-3-ene-1,2-dione**

10 To the above squarate (0.330 g, 1.10 mmol) in ethanol (25 mL) was added (R)-α-methylbenzylamine (0.135 mg, 1.11 mmol). The reaction was refluxed for 23 hours. Upon cooling, the product precipitated as a white solid 0.350g (84%): mp 258-260°C; [α]_D²⁵ -17.52 (DMSO); ¹H NMR (DMSO-d₆): δ 9.70 (s, 1H), 8.12 (d, 1H), 7.51-7.28 (m, 9H), 5.28 (m, 1H), 1.59 (d, 3H). IR (KBr): 3250, 1800, 1675, 1600 cm⁻¹; MS (m/z) 377 (MH⁺).

15 Elemental analysis for C₁₉H₁₅F₃N₂O₃
 Calc'd: C, 60.64; H, 4.02; N, 7.44.
 Found: C, 60.40; H, 4.01; N, 7.21.

EXAMPLE 7

20 **(R)-4-{2-[1-(4-Nitro-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzonitrile**

25 To the squarate of Example 1, step 1 (0.598 g, 2.47 mmol) in ethanol (50 mL) was added (R)-α-methyl-4-nitrobenzylamine hydrochloride (0.50 g, 2.5 mmol) and N,N-diisopropylethylamine (0.43 g, 2.5 mmol). The mixture was heated at reflux for 16 hours. After cooling the precipitate was filtered off to afford 0.70 g (78%) of product as an orange solid: mp 290-295°C; [α]_D²⁵ -100.52 (DMSO); ¹H NMR (DMSO-d₆): δ 9.98 (s, 1H), 8.32 (d, 1H), 8.25 (d, 2H), 7.79 (d, 2H), 7.68 (d, 2H), 7.57 (d, 2H), 5.42 (m, 1H), 1.61 (d, 3H). IR (KBr): 3200, 2220, 1790, 1670, 1600
30 cm⁻¹; MS (m/z) 362 (M⁺).

 Elemental analysis for C₁₉H₁₄N₄O₄
 Calc'd: C, 62.98; H, 3.89; N, 15.46.
 Found: C, 62.38; H, 3.73; N, 14.95.

35

EXAMPLE 8**3-[3,4-Dioxo-2-((R)-1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile**

5

Step 1) Preparation of 3-(3,4-dioxo-2-ethoxy-cyclobut-1-enylamino)-benzonitrile

3-Aminobenzonitrile (2.06 g, 17.4 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (2.97 g, 17.5 mmol) in absolute ethanol (50 mL). The mixture was heated at reflux overnight. The mixture was cooled and the resulting yellow precipitate was collected by vacuum filtration. Yield: 3.40 g (81%); ¹H NMR (DMSO-d₆): δ 10.95 (s, 1H), 7.75-7.40 (m, 4H), 4.73 (q, 2H), 1.39 (t, 3H).

15 **Step 2)** Preparation of 3-[3,4-dioxo-2-((R)-1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile

To the above squarate (1.00 g, 4.13 mmol) in ethanol (100 mL) was added (R)-α-methylbenzylamine (0.53 mL, 4.1 mmol). The mixture was heated at reflux overnight and vacuum filtered. The precipitate was triturated twice with hot methanol to afford 0.80 g (61%) of product as a pale yellow solid: mp 289-290°C (dec); [α]_D²⁵ -13.9 (DMSO); ¹H NMR (DMSO-d₆): δ 9.72 (s, 1H), 8.25 (d, 1H), 7.90-7.28 (m, 9H), 5.30 (m, 1H), 1.60 (d, 3H). IR (KBr): 3200, 2220, 1790, 1650, 1600 cm⁻¹; MS (m/z) 317 (M⁺).

25

Elemental analysis for C₁₉H₁₅N₃O₂

Calc'd: C, 71.91; H, 4.76; N, 13.24.

Found: C, 71.80; H, 4.61; N, 13.33.

EXAMPLE 9**4-[3,4-Dioxo-2-(1-methyl-1-phenyl-ethylamino)-
cyclobut-1-enylamino]-benzonitrile**

5

To the squarate of Example 1, step 1 (0.81 g, 3.3 mmol) in ethanol (30 mL) was added α,α -dimethylbenzylamine (0.45 g, 3.3 mmol). The mixture was heated at reflux for 20 hours. After cooling the precipitate was filtered off and chromatographed ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) to afford 0.41 g (37%) of product as yellow solid: mp $>300^\circ\text{C}$; ^1H NMR ($\text{DMSO}-d_6$): δ 10.08 (s, 1H), 8.38 (s, 1H), 7.79 (d, 2H), 7.61 (d, 2H), 7.48-7.27 (m, 5H), 1.78 (s, 6H). IR (KBr): 3200, 2230, 1790, 1675, 1600 cm^{-1} ; MS (m/z) 331 (M^+).

10

Elemental analysis for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}_2 \cdot (0.1 \text{ CH}_3\text{OH}) \cdot (0.05 \text{ CH}_2\text{Cl}_2)$

15

Calc'd: C, 71.43; H, 5.21; N, 12.40.

Found: C, 71.30; H, 5.33; N, 12.69.

EXAMPLE 10

20

**4-[3,4-Dioxo-2-((R)-1-phenyl-propylamino)-
cyclobut-1-enylamino]-benzonitrile**

25

To the squarate of Example 1, step 1 (1.79 g, 7.39 mmol) in ethanol (30 mL) was added (R)-1-phenyl-propylamine (1.00 g, 7.40 mmol). The mixture was heated at reflux for 18 hours, cooled slightly and vacuum filtered to afford 1.76 g (72%) of product as a yellow solid: mp $242-243^\circ\text{C}$; $[\alpha]^{25}_{\text{D}} -52.73$ (DMSO); ^1H NMR ($\text{DMSO}-d_6$): δ 9.84 (s, 1H), 8.12 (br d, 1H), 7.76 (d, 2H), 7.56 (d, 2H), 7.42-7.27 (m, 5H), 5.06 (m, 1H), 1.94 (m, 2H), 0.90 (t, 3H). IR (KBr): 3200, 2220, 1790, 1670, 1600 cm^{-1} ; MS (m/z) 331 (M^+).

30

Elemental analysis for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}_2$

Calc'd: C, 72.49; H, 5.17; N, 12.68.

Found: C, 72.42; H, 5.01; N, 12.73.

- 17 -

EXAMPLE 11**4-[3,4-Dioxo-2-((S)-1-phenyl-propylamino)-
cyclobut-1-enylaminol]-benzonitrile**

5

To the squarate of Example 1, step 1 (1.79 g, 7.39 mmol) in ethanol (30 mL) was added (S)-1-phenyl-propylamine (1.00 g, 7.40 mmol). The mixture was heated at reflux for 18 hours, cooled slightly and vacuum filtered to afford 1.61 g (66%) of product as a yellow solid: mp 241-243°C ; $[\alpha]^{25}_D +52.33$ (DMSO); ^1H NMR (DMSO- d_6): δ 9.84 (s, 1H), 8.21 (br d, 1H), 7.76 (d, 2H), 7.56 (d, 2H), 7.42-7.27 (m, 5H), 5.06 (m, 1H), 1.94 (m, 2H), 0.90 (t, 3H). IR (KBr): 3200, 2220, 1790, 1670, 1600 cm^{-1} ; MS (m/z) 331 (M^+).

Elemental analysis for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}_2$
15 Calc'd: C, 72.49; H, 5.17; N, 12.68.
Found: C, 72.17; H, 5.04; N, 12.80.

EXAMPLE 12

20

4-[3,4-Dioxo-2-(benzylamino)-cyclobut-1-enylaminol]-benzonitrile

To the squarate of Example 1, step 1 (1.00 g, 4.13 mmol) in ethanol (30 mL) was added benzylamine (0.45 mL, 4.1 mmol). The mixture was heated at reflux for 18 hours, cooled slightly and vacuum filtered. The precipitate was triturated with hot
25 methanol to afford 0.78 g (62%) of product as yellow solid: mp 288-290°C (dec); ^1H NMR (DMSO- d_6): δ 9.91 (s, 1H), 8.10 (m, 1H), 7.79 (d, 2H), 7.75 (d, 2H), 7.55 (d, 2H), 7.91-7.78 (m, 5H), 4.82 (d, 2H). IR (KBr): 3190, 2220, 1790, 1660, 1575 cm^{-1} ; MS (m/z) 303 (M^+).

30 Elemental analysis for $\text{C}_{18}\text{H}_{13}\text{N}_3\text{O}_2$
Calc'd: C, 71.28; H, 4.32; N, 13.85.
Found: C, 71.07; H, 4.16; N, 12.89.

- 18 -

EXAMPLE 13**(R)-4-{2-[1-(4-Methyl-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzonitrile**

5

To the squarate of Example 1, step 1 (1.00 g, 4.13 mmol) in ethanol (30 mL) was added (R)-1-(*p*-tolyl)-ethylamine (0.56 g, 4.1 mmol). The mixture was heated at reflux for 18 hours, cooled slightly and vacuum filtered to afford 1.02 g (75%) of product as a yellow solid: mp >300°C ; $[\alpha]^{25}_D$ -56.01 (DMSO); ^1H NMR (DMSO- d_6): δ 9.81 (s, 1H), 8.10 (m, 1H), 7.76 (d, 2H), 7.55 (d, 2H), 7.29 (d, 2H), 7.19 (d, 2H), 5.26 (m, 1H), 1.57 (d, 3H). IR (KBr): 3200, 2220, 1790, 1670, 1600 cm^{-1} ; MS (m/z) 331 (M^+).

10

Elemental analysis for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}_2$

15

Calc'd: C, 72.49; H, 5.17; N, 12.68.

Found: C, 72.42; H, 5.07; N, 12.82.

EXAMPLE 14

20

(R)-4-{2-[1-(4-Methoxy-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzonitrile

25

To a solution of (1R, 1'R)-N-(1'-phenylethyl)-1-(4"-methoxyphenyl)-ethylamine (1.37 g, 5.36 mmol; prepared as in *J. Med Chem.* 1992, 35, 2327) and ammonium formate (1.01 g, 16.0 mmol) in methanol (125 mL) was added 10% palladium on activated carbon. The suspension was refluxed for 2 h, filtered through Celite and concentrated. The squarate of Example 1, step 1 (1.00 g, 4.13 mmol) was added to a solution of the resulting residue in ethanol (30 mL). The mixture was heated at reflux for 18 h, cooled slightly and vacuum filtered. The precipitate was chromatographed ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) and recrystallized ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) to afford 0.21 g (15%) of product as a yellow solid: mp >300°C ; $[\alpha]^{25}_D$ -46.95 (DMSO); ^1H NMR (DMSO- d_6): δ 9.89 (s, 1H), 8.13 (d, 1H), 7.77 (d, 2H), 7.56 (d, 2H), 7.34 (d, 2H), 6.95 (d, 2H), 5.23 (m, 1H), 3.73 (s, 3H), 1.57 (d, 3H). IR (KBr): 3200, 2200, 1800, 1670, 1575 cm^{-1} ; MS (m/z) 347 (M^+).

35

- 19 -

Elemental analysis for $C_{20}H_{17}N_3O_3 \cdot (0.03 CH_2Cl_2)$

Calc'd: C, 68.75; H, 4.91; N, 12.01.

Found: C, 68.40; H, 4.74; N, 11.89.

5

EXAMPLE 15

(R)-4-(3,4-Dioxo-2-[1-(4-trifluoromethoxy-phenyl)-ethylamino]-
-cyclobut-1-enylamino)-benzonitrile

10 To a solution of (1R, 1'R)-N-(1'-phenylethyl)-1-(4"-trifluoromethoxyphenyl)-ethylamine (1.92 g, 6.21 mmol; prepared as in *J. Med Chem.* 1992, 35, 2327) and ammonium formate (1.17 g, 18.6 mmol) in methanol (150 mL) was added 10% palladium on activated carbon. The suspension was refluxed for 2 h, filtered through Celite and concentrated. The squarate of Example 1, step 1 (1.00 g, 4.13 mmol) was
15 added to a solution of the resulting residue in ethanol (35 mL). The mixture was heated at reflux for 18 h, cooled slightly and vacuum filtered. The precipitate was combined with a second crop of solid obtained from the cooled filtrate, chromatographed (CH_3OH/CH_2Cl_2) and recrystallized (CH_3OH/CH_2Cl_2) to afford
20 0.74 g (45%) of product as a white solid: mp 281-284°C (dec); $[\alpha]^{25}_D$ -55.94 (DMSO); 1H NMR (DMSO- d_6): δ 9.94 (s, 1H), 8.22 (d, 1H), 7.78 (d, 2H), 7.60-7.51 (m, 4H), 7.40 (d, 2H), 5.33 (m, 1H), 1.60 (d, 3H). IR (KBr): 3200, 2200, 1800, 1670, 1560 cm^{-1} ; MS (m/z) 401 (M^+).

Elemental analysis for $C_{20}H_{14}F_3N_3O_3$

25 Calc'd: C, 59.85; H, 3.52; N, 10.47.

Found: C, 59.94; H, 3.38; N, 10.43.

EXAMPLE 16

30

4-[3,4-Dioxo-2-(2,2,2-trifluoro-1-phenyl-ethylamino)-
cyclobut-1-enylamino]-benzonitrile

To a solution of N-2,2,2-trifluoro-1-phenylethyl-N-1'-(phenyl)ethylamine (1.65 g, 6.22 mmol; prepared as in *J. Org. Chem.* 1977, 42, 2436) and ammonium
35 formate (1.17 g, 18.6 mmol) in methanol (150 mL) was added 10% palladium on

- 20 -

activated carbon. The suspension was refluxed for 4 h, filtered through Celite and concentrated to a volume of approximately 10 mL. The squarate of Example 1, step 1 (1.00 g, 4.13 mmol) and ethanol (20 mL) were added and the mixture was heated at reflux for 18 h, cooled slightly and vacuum filtered to remove a small amount of solid. The filtrate was chromatographed (CH₃OH/CH₂Cl₂) and the resulting yellow solid crystallized from chloroform and ether to afford 0.72 g (47%) of product as a pale yellow solid: mp 206-207°C; ¹H NMR (DMSO-d₆): δ 9.99 (s, 1H), 8.88 (d, 1H), 7.82 (d, 2H), 7.60-7.46 (m, 9H), 5.98 (m, 1H), 3.73 (s, 3H). IR (KBr): 3200, 2200, 1800, 1690, 1570 cm⁻¹; MS (m/z) 371 (M⁺).

10

Elemental analysis for C₁₉H₁₂F₃N₃O₂

Calc'd: C, 61.46; H, 3.26; N, 11.32.

Found: C, 61.26; H, 3.16; N, 11.23.

15

EXAMPLE 17

(R)-4-[3,4-Dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-3-methyl-benzonitrile

20 **Step 1)** Preparation of 4-(3,4-Dioxo-2-ethoxy-cyclobut-1-enylamino)-3-methylbenzonitrile

4-Amino-3-methylbenzonitrile (1.94 g, 14.7 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (2.53 g, 14.9 mmol) in acetonitrile (5 mL). After refluxing the mixture for 24 h a second portion of 3,4-diethoxy-3-cyclobutene-1,2-dione (1.15 g, 6.76 mmol) was added and heating was continued for an additional 48 h. The reaction mixture was diluted with ethyl acetate (50 mL), stirred vigorously and filtered free of undissolved solid. The filtrate was chromatographed (CH₃OH/CH₂Cl₂) to afford 0.90 g (24%) of product as a yellow solid: ¹H NMR (DMSO-d₆): δ 10.50 (s, 1H), 7.76-7.63 (m, 2H), 7.31 (d, 1H), 4.71 (q, 2H), 2.33 (s, 3H), 1.38 (t, 3H).

30

Step 2) Preparation of (R)-4-[3,4-Dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-3-methyl-benzonitrile

35

- 21 -

To the above squarate (0.90 g, 3.51 mmol) in ethanol (40 mL) was added (R)- α -methylbenzylamine (0.45 mL, 3.49 mmol). The mixture was heated at reflux for 18 h. The resulting clear solution was concentrated and the residue chromatographed (CH₃OH/CH₂Cl₂) to afford 0.98 g (85%) of product as a yellow solid: mp 110-130°C (dec); [α]_D²⁵ -40.91 (DMSO); ¹H NMR (DMSO-d₆): δ 8.95 (s, 1H), 8.58 (d, 2H), 7.70-7.28 (m, 8H), 5.36 (m, 1H), 2.33 (s, 3H), 1.61 (d, 3H). IR (KBr): 3250, 2220, 1790, 1690, 1590 cm⁻¹; MS (m/z) 332 (MH⁺).

Elemental analysis for C₂₀H₁₇N₃O₂·(0.10 CH₂Cl₂)

10 Calc'd: C, 71.03; H, 5.10; N, 12.36.
 Found: C, 71.37; H, 5.09; N, 12.61.

EXAMPLE 18

15 (R)-4-[3,4-Dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-
 3-ethyl-benzonitrile

Step 1) Preparation of 4-(3,4-Dioxo-2-ethoxy-cyclobut-1-enylamino)-3-ethyl-benzonitrile

20 4-Amino-3-ethylbenzonitrile (2.00 g, 13.7 mmol) was added to a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (2.30 g, 13.5 mmol) in acetonitrile (5 mL). After refluxing the mixture for 24 h a second portion of 3,4-diethoxy-3-cyclobutene-1,2-dione (1.15 g, 6.76 mmol) was added and heating was continued for an additional
25 24 h. The reaction mixture was diluted with ethyl acetate (45 mL), stirred vigorously and filtered free of undissolved solid. The filtrate was concentrated and the resulting residue was purified by chromatographed (CH₃OH/CH₂Cl₂) and trituration with ether to afford 0.86 g (24%) of product as a light yellow solid: ¹H NMR (DMSO-d₆): δ 10.57 (s, 1H), 7.77-7.66 (m, 2H), 7.31 (d, 1H), 4.71 (q, 2H), 2.73 (q, 2H), 1.37 (t, 3H), 1.13 (t, 3H).
30

Step 2) Preparation of (R)-4-[3,4-Dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-3-ethyl-benzonitrile

- 22 -

To the above squarate (0.85 g, 3.14 mmol) in ethanol (25 mL) was added (R)- α -methylbenzylamine (0.41 mL, 3.18 mmol). The mixture was heated at reflux for 18 h, cooled slightly and suction filtered. The filtrate was cooled by gradual evaporation of solvent and the precipitate which formed was collected in two crops to afford 0.76 g (70%) of product as an off-white solid: mp 206-207°C (dec); $[\alpha]^{25}_D$ -45.25 (DMSO); 1H NMR (DMSO- d_6): δ 9.98 (s, 1H), 8.55 (d, 2H), 7.68-7.29 (m, 8H), 5.37 (m, 1H), 2.69 (q, 2H), 1.61 (d, 3H), 1.20 (t, 3H). IR (KBr): 3200, 2200, 1800, 1670, 1570 cm^{-1} ; MS (m/z) 345 (M^+).

10 Elemental analysis for $C_{21}H_{19}N_3O_2$
Calc'd: C, 73.03; H, 5.54; N, 12.17.
Found: C, 72.69; H, 5.52; N, 12.18.

EXAMPLE 19

15

(R)-N-(4-Cyano-phenyl)-N-[3,4-dioxo-2-(1-phenyl-ethylamino)-
cyclobut-1-enyl]-acetamide

To a stirred solution of the squarate of Example 1, step 2 (1.77 g, 5.58 mmol) in N,N-dimethylformamide (50 mL) was added, in one portion, sodium hydride (as a 60% dispersion in mineral oil; 0.252 g, 6.30 mmol). The frothy suspension was stirred at rt for 15 min and then at 0°C for an additional 1 h. Acetic anhydride (0.58 mL, 6.15 mmol) was added and the reaction mixture was stirred at 0°C for 1.5 h and then allowed to warm to rt. After an additional 1 h of stirring the reaction solution was concentrated. The resulting yellow solid was washed with successive portions of acetone, methylene chloride and ethyl acetate. The combined washings were concentrated and the resulting residue chromatographed to afford 0.48 g (24%) of product as an off-white solid: mp 240-243°C ; $[\alpha]^{25}_D$ -94.66 (DMSO); 1H NMR (DMSO- d_6): δ 8.29 (d, 1H), 7.96 (d, 2H), 7.69 (d, 2H), 7.45-7.25 (m, 5H), 5.49 (m, 1H), 2.06 (s, 3H), 1.59 (d, 3H). IR (KBr): 3340, 2230, 1800, 1740, 1690, 1610 cm^{-1} ; MS (m/z) 359 (M^+).

Elemental analysis for $C_{21}H_{17}N_3O_3$. (0.05 CH_2Cl_2)
Calc'd: C, 69.53; H, 4.74; N, 11.56.
Found: C, 69.16; H, 4.74; N, 11.53.

35

Smooth muscle relaxing activity of the compounds of this invention was established in accordance with standard pharmaceutically accepted test procedures in representative compounds as follows:

5

Sprague-Dawley rats (150-200 g) are rendered unconscious by CO₂ asphyxiation and then euthanized by cervical dislocation. The bladder is removed into warm (37 deg.C) physiological salt solution (PSS) of the following composition (mM): NaCl, 118.4; KCl, 4.7; CaCl₂, 2.5; MgSO₄, 4.7; H₂O, 1.2; NaHCO₃, 24.9; 10 KH₂PO₄, 1.2; glucose, 11.1; EDTA, 0.023; gassed with 95% O₂; 2/5% CO₂; pH 7.4. The bladder is opened and then cut into strips 1-2 mm in width and 7-10 mm in length. The strips are subsequently suspended in a 10 mL tissue bath under an initial resting tension of 1.5 g. The strips are held in place by two surgical clips one of which is attached to fixed hook while the other is attached to an isometric force transducer. 15 The preparations, which usually exhibit small spontaneous contractions, are allowed to recover for a period of 1 hour prior to a challenge with 0.1 uM carbachol. The carbachol is then washed out and the tissue allowed to relax to its resting level of activity. Following 1 further 30 min period of recovery an additional 15 mM KCl are introduced into the tissue bath. This increase in KCl concentration results in a large 20 increase in the amplitude of spontaneous contractions (and initiation of contractions in previously quiescent strips) superimposed upon a small increase in basal tone. Following stabilization of this enhanced level of contractile activity, incremental increases in the concentration of test compound or vehicle are introduced into the tissue bath. Contractile activity is measured for each compound or vehicle 25 concentration during the last min of a 30 min challenge.

Isometric force developed by the bladder strips is measured using a concentration required to elicit 50% inhibition of pre-drug contractile activity (IC₅₀ concentration) is calculated from this concentration-response curve. The maximum 30 percentage inhibition of contractile activity evoked by a test compound is also recorded for concentrations of test compound < or equal to 30 µM.

- 24 -

The results of this study are shown in Table I.

Table I

5 **Inhibition of Contractions in Isolated Rat Bladder Strips**

Compound	n	IC ₅₀	Inhibition of Force (%) at (x) μ M
Example 1	6	0.056 μ M	-
Example 4	3	2.3 μ M	
Example 5	3	-	38% (30 μ M)
Example 9	4	-	22% (30 μ M)
Example 11	4	-	28% (30 μ M)

10 Hence, the compounds of this invention have a pronounced effect on smooth
muscle contractility and are useful in the treatment of urinary incontinence, irritable
bladder and bowel disease, asthma, hypertension, stroke, and similar diseases as
mentioned above, which are amenable to treatment with potassium channel activating
compounds by administration, orally, parenterally, or by aspiration to a patient in
need thereof.


15

- 25 -

What is claimed is:

-1-

5 A compound of the formula:




wherein:

10 R₁ is hydrogen, C₁-10 straight or branched chain alkyl, C₃-10 cyclic or bicyclic alkyl, alkanoyl of 2 to 7 carbon atoms, alkylsulfonyl of 1 to 7 carbon atoms, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or

15 arylalkylsulfonyl of 7 to 12 carbon atoms;

R₂ is hydrogen, C₁-10 straight or branched chain alkyl or C₃-10 cyclic or bicyclic alkyl;

20 A is a group of the following formula:




- 26 -

wherein:

R7 and R8, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, carboalkoxy of 2 to 7 carbon atoms, hydroxyl or hydrogen;

or, A is Het where Het is selected from the following:



- 27 -

wherein:

5 R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, C₁₋₆ alkylsulfonamido, C₂₋₆ alkylcarboxamido, nitro, cyano, carboxyl, chloro, bromo, fluoro, iodo;

n is an integer from 0 to 6;

10 R₃ and R₄ are, independent from each other, hydrogen, C₁₋₁₀ straight or branched chain alkyl, or C₃₋₁₀ cyclic or bicyclic alkyl; C₁₋₁₀ perfluoro alkyl, C₁₋₁₀ hydroxyalkyl, C₂₋₁₀ alkoxyalkyl, fluoro; or, when taken together, form a spirocyclic ring containing a total of 3-7 carbon atoms;


15 R₅ and R₆, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, C₂₋₇ carboalkoxy, hydroxyl, or hydrogen;

25 or a pharmaceutically acceptable salt thereof.

(2) A compound of Claim 1 wherein:

30 A is a group of the following formula:

- 28 -




wherein:

5

R7 and R8, independent from each other, are selected from the following: cyano, nitro, amino, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, hydrogen;

or A is Het where Het is selected from the following:



10

wherein:

R9 is as stated above;

15

n = 0;

- 29 -

R₃ and R₄ are, independent from each other, hydrogen, C₁₋₁₀ straight or branched chain alkyl, C₁₋₁₀ perfluoro alkyl, C₁₋₁₀ hydroxyalkyl or fluoro;

5 R₅ and R₆, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, chloro, bromo, fluoro, iodo, carboxyl, C₂₋₇ carboalkoxy, hydroxyl, hydrogen;

10

or a pharmaceutically acceptable salt thereof.

(3) The compound of Claim 1 which is 4-[3,4-dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile.

15

(4) The compound of Claim 1 which is 3-(5-bromo-pyridin-3-ylamino)-4-(1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione.

20

(5) The compound of Claim 1 which is 3-(2-methoxy-5-trifluoromethyl-phenylamino)-4-(1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione.

(6) The compound of Claim 1 which is 3-(1-phenyl-ethylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione.

25

(7) The compound of Claim 1 which is 3-(4-trifluoromethoxy-phenylamino)-4-(1-phenyl-ethylamino)-cyclobut-3-ene-1,2-dione.

(8) The compound of Claim 1 which is 4-{2-[1-(4-nitro-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzonitrile.

30

(9) The compound of Claim 1 which is 3-[3,4-dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile.


35

(10) The compound of Claim 1 which is 4-[3,4-dioxo-2-(1-methyl-1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile.

- 30 -

- (11) The compound of Claim 1 which is 4-[3,4-dioxo-2-(1-phenyl-propylamino)-cyclobut-1-enylamino]-benzonitrile.
- 5 (12) The compound of Claim 1 which is 4-[3,4-dioxo-2-(benzylamino)-cyclobut-1-enylamino]-benzonitrile.
- (13) The compound of Claim 1 which is 4-{2-[1-(4-methyl-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzonitrile.
- 10 (14) The compound of Claim 1 which is 4-{2-[1-(4-methoxy-phenyl)-ethylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzonitrile.
- (15) The compound of Claim 1 which is 4-{3,4-dioxo-2-[1-(4-trifluoromethoxy-phenyl)-ethylamino]-cyclobut-1-enylamino}-benzonitrile.
- 15 (16) The compound of Claim 1 which is 4-[3,4-dioxo-2-(2,2,2-trifluoro-1-phenyl-ethylamino)-cyclobut-1-enylamino]-benzonitrile.
- (17) The compound of Claim 1 which is 4-[3,4-dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-3-methyl-benzonitrile.
- 20 (18) The compound of Claim 1 which is 4-[3,4-dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enylamino]-3-ethyl-benzonitrile.
- 25 (19) The compound of Claim 1 which is N-(4-cyano-phenyl)-N-[3,4-dioxo-2-(1-phenyl-ethylamino)-cyclobut-1-enyl]-acetamide.
- (20) A method for reducing the adverse effects of smooth muscle contractions which comprises administering, orally or parenterally, to a patient in need thereof, a compound of the formula:
- 30

- 31 -




(I)

wherein:

5 R_1 is hydrogen, C1-10 straight or branched chain alkyl, C3-10 cyclic or bicyclic alkyl, alkanoyl of 2 to 7 carbon atoms, alkylsulfonyl of 1 to 7 carbon atoms, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or
10 arylalkylsulfonyl of 7 to 12 carbon atoms;

R_2 is hydrogen, C1-10 straight or branched chain alkyl or C3-10 cyclic or bicyclic alkyl;

15 A is a group of the following formula:



wherein:


20 R_7 and R_8 , independent from each other, are selected from the following: cyano, nitro, amino, C1-6 alkyl,

- 32 -

5 C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, carboalkoxy of 2 to 7 carbon atoms, hydroxyl or hydrogen;

10

or, A is Het where Het is selected from the following:



wherein:

- 33 -

R₉ is hydrogen, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, C₁₋₆ alkylsulfonamido, C₂₋₆ alkylcarboxamido, nitro, cyano, carboxyl, chloro, bromo, fluoro, iodo;

5

n is an integer from 0 to 6;

R₃ and R₄ are, independent from each other, hydrogen, C₁₋₁₀ straight or branched chain alkyl, or C₃₋₁₀ cyclic or bicyclic alkyl; C₁₋₁₀ perfluoro alkyl, C₁₋₁₀ hydroxyalkyl, C₂₋₁₀ alkoxyalkyl, fluoro; or, when taken together, form a spirocyclic ring containing a total of 3-7 carbon atoms;

10

R₅ and R₆, independent from each other, are selected from the following: cyano, nitro, amino, C₁₋₆ alkyl, C₁₋₆ perfluoroalkyl, C₁₋₆ alkoxy, C₁₋₆ perfluoroalkoxy, amino, C₁₋₁₂ mono- or dialkylamino, sulfonamide, C₁₋₆ alkylsulfonamido, C₆₋₁₂ arylsulfonamido, C₂₋₆ alkylcarboxamido, C₇₋₁₂ arylcarboxamido, C₁₋₆ alkylsulfonyl, C₁₋₆ perfluoroalkylsulfonyl, C₆₋₁₂ arylsulfonyl, chloro, bromo, fluoro, iodo, 1-imidazolyl, carboxyl, C₂₋₇ carboalkoxy, hydroxyl, or hydrogen;

15

20

or a pharmaceutically acceptable salt thereof.

25

(21) The method of Claim 20 in which the smooth muscle adversely contracting causes urinary incontinence.

(22) The method of Claim 20 in which the smooth muscle adversely contracting causes irritable bowel syndrome.

30

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/14597

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/84 C07C49/15 C07C225/20 A61K31/12 A61K31/44
C07D211/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 354 763 (BUTERA JOHN A ET AL) 11 October 1994 see the whole document	1-19
P,X	& WO,A,95 14005 (AMERICAN HOME PRODUCTS CORPORATION) 26 May 1995 see the whole document --- -/--	1-19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

22 March 1996

Date of mailing of the international search report

17.04.96

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 95/14597

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 121, no. 11, 12 September 1994 Columbus, Ohio, US; abstract no. 133584g, SHUICHI, T. ET AL. 'Preparation of 1,2-diaminocyclobutene-3,4-diones and their pharmaceutical use' page 979; see abstract	1-19
X	& JP,A,06 092 915 (SUM ITOMO METAL IND) 5 April 1994 see the whole document	1-19
Y	EP,A,0 426 379 (BEECHAM GROUP PLC) 8 May 1991 cited in the application see the whole document	1-19
Y	EP,A,0 163 324 (IKEDA MOHANDO CO) 4 December 1985 cited in the application see the whole document	1-19
Y	US,A,4 390 701 (ALGIERI ALDO A ET AL) 28 June 1983 cited in the application see the whole document	1-19
Y	EP,A,0 496 561 (AMERICAN HOME PROD) 29 July 1992 see the whole document	1-19
Y	J.MED.CHEM., vol. 35, no. 25, 1992 WASHINGTON, pages 4720-4726, KINNEY, W.A. ET AL. 'Bioisosteric Replacement of the alpha-Amino Carboxylic Acid Functionality in 2-Amino-5-phosphopentanoic Acid Yields Unique 3,4-Diamino-3-cyclobutene-1,2-dione Containing NMDA Antagonists' see the whole document	1-19
Y	TRENDS IN PHARMACOLOGICAL SCIENCE, vol. 11, no. 10, October 1990 CAMBRIDGE, pages 417-422, EDWARDS, G. ET AL. 'Structure-Activity-Relationships of K+ Channel Openers ' * see in particular page 420, " Re-discovered K+ channel openers" *	1-19
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/14597

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO,A,94 29277 (SMITHKLINE BEECHAM PLC ;COATES WILLIAM JOHN (GB); RAWLINGS DEREK A) 22 December 1994 see the whole document ---	1-19
P,Y	EP,A,0 645 385 (SQUIBB BRISTOL MYERS CO) 29 March 1995 see the whole document -----	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/14597

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20-22 are directed to a method of treatment of the human/
animal body (Rule 39.1(iv)), the search has been carried out and based on
the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/14597

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US-A-5354763	11-10-94	AU-B-	1086695	06-06-95
		WO-A-	9514005	26-05-95
		US-A-	5401753	28-03-95
		US-A-	5403853	04-04-95
		US-A-	5403854	04-04-95
		US-A-	5397790	14-03-95

EP-A-0426379	08-05-91	AT-T-	115954	15-01-95
		AU-B-	625427	09-07-92
		AU-B-	6554490	02-05-91
		DE-D-	69015322	02-02-95
		DE-T-	69015322	18-05-95
		JP-A-	3151374	27-06-91
		US-A-	5147866	15-09-92

EP-A-0163324	04-12-85	JP-C-	1797894	28-10-93
		JP-B-	5008183	01-02-93
		JP-A-	60255756	17-12-85
		AU-B-	583511	04-05-89
		AU-B-	4325485	05-12-85
		CA-A-	1286669	23-07-91
		US-A-	4639523	27-01-87
		US-A-	4673747	16-06-87

US-A-4390701	28-06-83	AT-B-	384805	11-01-88
		AU-B-	541843	24-01-85
		AU-B-	8362082	25-11-82
		BE-A-	893236	18-11-82
		CA-A-	1190224	09-07-85
		CA-C-	1190225	09-07-85
		CH-A-	649527	31-05-85
		CH-A-	653989	31-01-86
		DE-A-	3218584	23-12-82
		DE-C-	3249715	11-07-91
		FR-A,B	2505835	19-11-82
		FR-A,B	2513250	25-03-83
		GB-A,B	2098988	01-12-82
		GB-A,B	2147899	22-05-85
		JP-C-	1625987	18-11-91
		JP-B-	2051425	07-11-90

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/14597

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4390701		JP-A- 57193427	27-11-82
		JP-C- 1790824	29-09-93
		JP-A- 2036159	06-02-90
		JP-B- 4078628	11-12-92
		LU-A- 84157	13-04-83
		NL-A- 8201999	16-12-82
		OA-A- 7103	31-01-87
		SE-B- 457081	28-11-88
		SE-A- 8203092	19-11-82
		SU-A- 1375127	15-02-88
		US-A- 4788184	29-11-88
		US-A- 4395553	26-07-83
		US-A- 4522943	11-06-85
		US-A- 4526973	02-07-85
		US-A- 4503051	05-03-85
		US-A- 4539316	03-09-85
		US-A- 4607105	19-08-86
		US-A- 4546188	08-10-85

EP-A-0496561	29-07-92	US-A- 5168103	01-12-92
		AT-T- 119873	15-04-95
		AU-B- 639629	29-07-93
		AU-B- 1030192	30-07-92
		CA-A- 2059704	23-07-92
		CZ-A- 9200144	19-01-94
		DE-D- 69201655	20-04-95
		DE-T- 69201655	13-07-95
		ES-T- 2071428	16-06-95
		HU-A- 61970	29-03-93
		JP-A- 4321654	11-11-92
		SK-A- 14492	08-02-95
		RU-C- 2039035	09-07-95
		US-A- 5240946	31-08-93
		ZA-A- 9200358	19-07-93

WO-A-9429277	22-12-94	NONE	

EP-A-0645385	29-03-95	AU-B- 7297594	30-03-95
		CA-A- 2130078	17-03-95
		CN-A- 1112561	29-11-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/14597

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0645385		CZ-A- 9402248	16-08-95
		FI-A- 944280	17-03-95
		HU-A- 70614	30-10-95
		JP-A- 7196648	01-08-95
		NO-A- 943428	17-03-95
		PL-A- 305047	20-03-95
